Journal
CELL COMMUNICATION AND SIGNALING
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12964-022-00862-y
Keywords
ACT001; Traumatic brain injury; Microglia cells; Neuroinflammation; AKT; NF kappa B; NLRP3 inflammasome
Categories
Funding
- National Natural Science Foundation of China [82171373, 82071404, 82001310, 81801236]
- Shanghai Jiao Tong University Medicine-Engineering Research Fund [YG2022ZD019, YG2021QN96]
- Shanghai Municipal Health Commission [20184Y0109]
- Shanghai Municipal Science and Technology Project [19411968100]
Ask authors/readers for more resources
This study found that ACT001 can alleviate neurodegeneration after TBI by reducing the activation of microglia cells. ACT001 can inhibit the production of pro-inflammatory cytokines induced by LPS, improve cellular apoptosis and tube formation, and its mechanism of action is related to the AKT/NF kappa B/NLRP3 pathway.
Background: Microglia-mediated neuroinflammatory response following traumatic brain injury (TBI) is considered as a vital secondary injury factor, which drives trauma-induced neurodegeneration and is lack of efficient treatment. ACT001, a sesquiterpene lactone derivative, is reportedly involved in alleviation of inflammatory response. However, little is known regarding its function in regulating innate immune response of central nervous system (CNS) after TBI. This study aimed to investigate the role and underlying mechanism of ACT001 in TBI. Methods: Controlled cortical impact (CCI) models were used to establish model of TBI. Cresyl violet staining, evans blue extravasation, neurobehavioral function assessments, immunofluorescence and transmission electron microscopy were used to evaluate therapeutic effects of ACT001 in vivo. Microglial depletion was induced by administering mice with colony stimulating factor 1 receptor (CSF1R) inhibitor, PLX5622. Cell-cell interaction models were established as co-culture system to simulate TBI conditions in vitro. Cytotoxic effect of ACT001 on cell viability was assessed by cell counting kit-8 and activation of microglia cells were induced by Lipopolysaccharides (LPS). Pro-inflammatory cytokines expression was determined by Real-time PCR and nitric oxide production. Apoptotic cells were detected by TUNEL and flow cytometry assays. Tube formation was performed to evaluate cellular angiogenic ability. ELISA and western blot experiments were used to determine proteins expression. Pull-down assay was used to analyze proteins that bound ACT001. Results: ACT001 relieved the extent of blood-brain barrier integrity damage and alleviated motor function deficits after TBI via reducing trauma-induced activation of microglia cells. Delayed depletion of microglia with PLX5622 hindered therapeutic effect of ACT001. Furthermore, ACT001 alleviated LPS-induced activation in mouse and rat primary microglia cells. Besides, ACT001 was effective in suppressing LPS-induced pro-inflammatory cytokines production in BV2 cells, resulting in reduction of neuronal apoptosis in HT22 cells and improvement of tube formation in bEnd.3 cells. Mechanism by which ACT001 functioned was related to AKT/NF kappa B/NLRP3 pathway. ACT001 restrained NF kappa B nuclear translocation in microglia cells through inhibiting AKT phosphorylation, resulting in decrease of NLRP3 inflammasome activation, and finally down-regulated microglial neuroinflammatory response. Conclusions: Our study indicated that ACT001 played critical role in microglia-mediated neuroinflammatory response and might be a novel potential chemotherapeutic drug for TBI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available